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Introduction: Among the several agents targeting the pro-
grammed cell death 1 (PD-1) pathway, pembrolizumab is
currently the only one approved for the treatment of patients
with NSCLC in association with a companion diagnostic
assay, the anti–PD-L1 immunohistochemical (IHC) 22C3
PharmDx (Agilent Technologies, Santa Clara, CA) using the
Dako Autostainer (Dako, Carpinteria, CA). However, the Dako
platform is not present in each pathology department, and
this technical limitation is a major problem for the diffusion
of the PD-L1 IHC predictive test for pembrolizumab.
Methods: The Italian Society of Anatomic Pathology and
Cytopathology and the Italian Association ofMedical Oncology
in an independent, multicenter study compared the in vitro
diagnostics PD-L1 IHC 22C3 pharmDx test (Agilent) on the
Dako Autostainer and the in vitro diagnostics Ventana PD-L1
(SP263) test on the Ventana BenchMark platform (Ventana
Medical Systems, Tucson,AZ).Using serial sections fromtissue
microarrays, 100 lung adenocarcinomas were locally stained
and scored in four centers with the same antibody batches.
Results: A high analytical correlation (more than 90% at the
lower 95% confidence interval [CI] value) between PD-L1
expression levels obtained with the 22C3 and SP263 assays
was observed. At the proposed clinically relevant cutoffs
(50% and 1%), the overall concordances between 22C3
and SP263 data were 0.99 (95% CI: 0.96–1) and 0.80 (95%
CI: 0.68–0.91), respectively. The lower agreement betweenJournal of Thoracic Oncology Vol. 12 No. 11: 1654-1663data obtainedwith the 22C3 and SP263 clones at the cutoff of
1% or higher was mainly related to the lower (about 80%)
interrater agreement at this cutoff with each clone.
Conclusions: These results indicate a high correlation be-
tween PD-L1 IHC expression data obtained with the Agilent
PD-L1 IHC 22C3 pharmDx and the Ventana PD-L1 (SP263)
tests in NSCLC and suggest that the two assays could be uti-
lized interchangeably as an aid to select patients for first-line
and second-line treatment with pembrolizumab and poten-
tially with other anti–PD-1/PD-L1 checkpoint inhibitors.
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Non–small cell lung cancer; PD-1; PD-L1;
Immunohistochemistry; Immunotherapy
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The immune checkpoint inhibitors anti–programmed
cell death 1 (PD-1)/programmed cell death ligand 1 (PD-
L1) (anti–PD-1/PD-L1) are currently changing the
approach to treatment of patients with (NSCLC). Over
the last 2 years, the U.S. Food and Drug Administration
(FDA) has granted approval to the anti–PD-1 inhibitors,
nivolumab (OPDIVO, Bristol-Myers Squibb, New York,
New York)1 and pembrolizumab (KEYTRUDA, Merck
Sharp and Dohme, Hoddesdon, United Kingdom)2 and
the anti–PD-L1 inhibitor atezolizumab (TECENTRIQ,
Genentech Oncology, South San Francisco, CA)3 for the
treatment of patients with advanced NSCLC with pro-
gression during or after first-line therapy. Nivolumab
and pembrolizumab have been approved by the Euro-
pean Medicines Agency (EMA) for the same indication.4,5
Recently, both the European and U.S. agencies have
extended the recommendations for pembrolizumab to
the first-line therapy of patients with advanced NSCLC.6,7
In addition, durvalumab (MEDI4736, AstraZeneca,
Wilmington, DE) and avelumab (MSB0010718C, Merck
KGaA and Pfizer, Darmstadt, Germany) are being inves-
tigated for the treatment of NSCLC.8–10
The expression of PD-L1 by means of immunohisto-
chemistry represents the most validated predictor of
response to anti–PD-1/PD-L1 inhibitors. Although it is
still a matter of controversy, results from clinical trials
and recent pooled and meta-analyses have shown
enhanced clinical benefit from anti–PD-1/PD-L1 therapy
in patients with PD-L1–positive tumors.11–15 Together
with anti–PD-1/PD-L1 inhibitors, different immunohis-
tochemical (IHC) assays have been developed to assess
the expression of PD-L1, and different antibodies, clones,
platforms, score systems, and cutoff values have been
introduced for and linked to a specific inhibitor.16 In
particular, PD-L1 IHC 28-8 PharmDx (Agilent Technolo-
gies, Santa Clara, CA/Dako Carpinteria, CA) has been
labeled a complementary diagnostic of nivolumab on the
basis of clinical evidence suggesting that patients affected
by PD-L1–positive NSCLC (with 1% of immunoreactive
tumor cells) had a higher clinical benefit from this treat-
ment.17 The complementary diagnostic Ventana PD-L1
(SP142) assay (Ventana Medical Systems, Tucson, AZ)
has been approved for therapy with atezolizumab in
considering of the enhanced survival observed in patients
with NSCLC with at least 50% of tumor cells expressing
PD-L1 or at least 10% of the tumor area occupied by PD-
L1–expressing tumor-infiltrating immune cells.18
Although these assays may provide useful information
to clinicians as complementary diagnostics, neither the
PD-L1 IHC 28-8 PharmDx nor Ventana PD-L1 (SP142)
assay are strictly required for treatment with nivolumab
or atezolizumab, respectively. Finally, the Ventana SP263clone is still under the FDA regulatory process and has
been developed for treatmentwith durvalumab by using a
positivity cutoff of 25% or more tumor cells.12 Currently,
only the PD-L1 IHC 22C3 pharmDx assay has been
approved by FDA and recommended by the EMA as a
companion diagnostic for pembrolizumab. Essentially,
pembrolizumab is the only PD-1/PD-L1 inhibitor that has
an FDA and EMA indication restricted to PD-L1–positive
tumors.6 The PD-L1 IHC 22C3 pharmDx test was designed
to detect PD-L1 in formalin-fixed, paraffin-embedded
NSCLC samples by using mouse monoclonal anti–PD-L1
clone (22C3) and the EnVision FLEX visualization system
on Autostainer Link 48 (Agilent).19 However, not every
pathology laboratory has the Dako Autostainer. This
represents a major drawback for diffusion of the PD-L1
IHC test in the clinical practice. A harmonization study
to analyze the results obtained with the 22C3 clone on the
Dako Autostainer and Ventana BenchMark platforms has
been recently presented.20 The overall concordance re-
ported in this study was 85% to 87% and was limited to
strongly positive tumors. Indeed, in all investigated cases
with weak positivity (tumor proportion score of 1%–
49%) the results were discordant. An additional limita-
tion of this approach is that the test was used under off-
label (not in vitro diagnostics [IVD]) conditions.
The IVD PD-L1 tests, Ventana PD-L1 (SP142) and the
Ventana PD-L1 (SP263) assays have been developed for
use on the Ventana BenchMark platforms, which are also
largely present in pathology laboratories. Previous
multicenter studies for the harmonization of clinically
tested diagnostic antibodies have clearly shown that the
immunostaining of NSCLC samples with the SP142 clone
is significantly weaker and the percentage of positive
tumor cells is lower than that obtained with the 22C3
and SP263 clones.21–24
To investigate the possibility of using a PD-L1 test
alternative to the PD-L1 IHC 22C3pharmDx assay for those
laboratories that do not have the Dako platform, we
designed a multicenter study to assess the technical pro-
cedures and interpretation ability in four different pa-
thology units with specific expertise in both thoracic
pathology and immunohistochemistry. The study aimed to
compare the PD-L1 expression evaluated by the IHC 22C3
PharmDx on the Dako Autostainer platform with that
observed by the SP263 on the Ventana BenchMark plat-
form in a large number of lung adenocarcinomas (ADC).
Materials and Methods
Organization of the Multicenter Study Anti–PD-
L1 IHC 22C3
The Italian Society of Anatomic Pathology and Cyto-
pathology and the Italian Association of Medical
Oncology identified a board of Italian pathologists and
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and are coauthors of this study. Four surgical pathology
departments (Center of Predictive Molecular Medicine,
Center of Predictive Molecular Medicine, Center for
Excellence on Aging and Translational Medicine, Uni-
versity of Chieti, Italy; Division of Pathology and Labo-
ratory Medicine, European Institute of Oncology, Milan,
Italy; Pathology Division, Department of Oncology, Uni-
versity of Turin, Turin, Italy; and Pathology Division,
Departments of Pathology, University of Naples Federico
II and University of Campania Luigi Vanvitelli, Naples,
Italy) were identified as referral centers for the PD-L1
multicenter study. All the selected centers had both
DAKO Autostainer and Ventana BanchMark IHC plat-
forms. The centers have been anonymized as center A,
center B, center C, and center D.Tissue Samples and TMA Preparation
A total of 100 formalin-fixed, paraffin embedded sam-
ples from consecutive resected lung adenocarcinomas
collected during the period 2014–2016 were used for the
preparation of tissue microarrays (TMAs). Lung tumors
specimens were provided from three of the four centers
participating in the study (centers A, B, and C). In each case,
the two representative areas with the highest percentage
of vital neoplastic cells were selected on 4-mm-thick, he-
matoxylin and eosin–stained sections and labeled with a
permanent marker. Corresponding areas on paraffin
blocks were numbered, captured with a 2-mm puncher on
a semi-automatic tissue micro arrayer (Galileo TMA
CK3500B, Integrated Systems Engineering Srl, Milan,
Italy), and transferred to recipient TMA blocks arranged in
pairs corresponding to single cases to allow an easy com-
parison. A core of human placental tissue was also placed
in each recipient block to provide a positive control and a
reference for orienting the slides under the microscope.
From eight TMA blocks, for a total of 200 cores, 20 (4-mm-
thick) sections per blockwere obtained and sent to the four
referral centers for subsequent IHC staining and analysis.
Each center alternatively received contiguous sections to
minimize differences in tumor morphology. Unstained
sections were prelabeled with a letter indicating the cor-
responding block (A, B, C, D, E, F, G, and H), as were the
clones to be used for the IHC staining.IHC Analysis
In each center, IHC analysis was conducted with IVD
versions of the PD-L1 IHC 22C3 pharmDx and the Ven-
tana PD-L1 (SP263) assays on the DAKO Autostainer
Link 48 and Ventana BanchMark platforms, respectively.
The detection and quantification of the percentage of
immunoreactive tumor cells was performed according to
the manufactures recommendations. Briefly, neoplasticcells were considered positive when any cell membrane
staining (partial or complete) was present, ignoring pure
cytoplasmic immunoreaction. Staining on immune cells
was also disregarded. Quantification of immunoreactive
neoplastic cells was obtained by evaluating the ratio
between stained carcinoma cells and all viable carci-
noma cells. The IHC staining of neoplastic cell was
assessed in each (2-mm) TMA core of the same case, and
the mean percentage of PD-L1 expression between the
two cores was reported. To maximize the standardiza-
tion of the scoring procedures, a miniguide summarizing
the Agilent and Ventana evaluation protocols was sent to
the four centers before the analytical process. The senior
pathologist in each center evaluated the IHC staining. For
three centers (A, B, and C), the pathologist had attended
international training workshops on the detection of
PD-L1 immunoreaction as implemented by Agilent and
Ventana; from now on, we will refer to them as trained
centers. The referring pathologist of the fourth center (D)
had not attended any PD-L1–specific training workshop
at the time of this study.Statistical Analysis
PD-L1 expression values measured in the four
pathology centers for each of the two IHC assays were
investigated for correlation by using the intraclass cor-
relation coefficient.25 The agreement among raters at the
clinically relevant PD-L1 expression cutoff levels for
pembrolizumab (1% and 50%) were assessed by the
weighted kappa (k) of Fleiss’s k interrater agreement
analysis, as appropriate.26 The relationship between PD-
L1 expression levels evaluated by the 22C3 and SP263
assays was calculated using the concordance correlation
coefficient, Pearson’s precision analysis.27 At the clini-
cally relevant cutoff, the correlation between data
generated in the different centers by the 22C3 and
SP263 clones was calculated using the weighed k or
Light’s k statistics, as appropriate.26 A correlation higher
than 90% is a typical within-assay agreement for IHC.28
A p value less than 0.05 was considered significant. All
statistical analyses were performed using IBM SPSS
statistics software, version 22 (IBM Corp., Armonk, NY).
Results
Scoring of the 22C3 and SP263 IHC assays showed
qualitative differences in the staining patterns. Staining
intensity was slightly stronger and more dense (less
granular) with the SP263 clone. Although intensity is not
included in the PD-L1 IHC scoring system, a higher in-
tensity can make it easier to recognize the staining at low
magnification. Therefore, the percentage of positive cells
at low magnification usually seemed to be higher with
the SP263 clone. However, at a higher magnification,
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staining were also scored positive, as otherwise recom-
mended by the manufacturers of both assays, a very
similar percentage of positive cells was obtained in each
case with the two IHC tests. A paradigmatic example of
IHC staining with the 22C3 and SP263 clones is shown in
Figure 1.
The distribution of PD-L1 expression levels detected
by the 22C3 and SP263 tests in each of the four
participating pathology centers are reported in the dot-
and-line diagram of Figure 2. The intraclass correlation
coefficients for the 22C3 and SP263 clones were 0.973
(95% CI [confidence interval]: 0.964–0.981) and 0.968
(95% CI: 0.957–0.977), respectively. When only the
three trained centers were considered, the intraclass
correlation coefficients for data obtained with the 22C3
and SP263 clones were 0.976 (95% CI: 0.966–0.983) and
0.977 (95% CI: 0.969–0.984), respectively.Figure 1. A typical example of immunohistochemical staining
22C3 pharmDx test (Agilent) on the Dako Autostainer (A) and
(SP263) test on the on the Ventana BenchMark platform (C) is rep
percentage of positive tumor cells with the SP263 clone seem
staining. However, at higher magnification (200–400), if a we
cording to the manufacturer recommendations, the two tests sh
(magnified frames B and D).At a cutoff of 50% or higher, the Fleiss’s k interrater
agreement values were 0.931 (95% CI: 0.851–1.011)
and 0.942 (95% CI: 0.862–1.022) for data obtained with
the 22C3 and SP263 clones, respectively. Restricted to
the three trained centers, the agreement values were
0.946 (95% CI: 0.833–1.059) and 0.973 (95% CI: 0.860–
1.087) for the 22C3 and SP263 data, respectively
(Table 1).
At the cutoff of 1% or higher, the Fleiss’s k interrater
agreement values were 0.754 (95% CI: 0.674– 0.834)
and 0.798 (95% CI: 0.718–0.878) for the 22C3 and
SP263 data, respectively. Among the three trained cen-
ters, the Fleiss’s k interrater agreement values were
0.769 (95% CI: 0.655–0.882) and 0.82 (95% CI: 0.709–
0.936) for the 22C3 and SP263 data, respectively.
The correlation between the 22C3 and SP263
expression levels in each of the four centers is shown in
scatter diagrams (Fig. 3A–D). Each point in the diagramwith the programmed death ligand 1 immunohistochemical
the in vitro diagnostics Ventana programmed death ligand 1
orted. Note that at a low magnification (100) (A and C), the
s to be higher owing to the slightly higher intensity of the
ak and incomplete cell membrane staining is considered ac-
ow a very similar percentage of immunoreactive tumor cells
Figure 2. Dot-and-line diagram of the distribution and correlation of programmed death ligand 1 (PD-L1) expression levels
detected by the PD-L1 immunohistochemistry (IHC) 22C3 pharmDx test (Agilent), on the Dako Autostainer (top) and the
in vitro diagnostics Ventana PD-L1 (SP263) test on the Ventana BenchMark platform (bottom) in each of the four referral
pathology centers. Data are often superimposed, mainly for cases with low PD-L1 expression levels.
1658 Marchetti et al Journal of Thoracic Oncology Vol. 12 No. 11indicates the percentage of positive tumor cells with the
anti–PD-L1 22C3 (on the x axis) and SP263 (on the y
axis) assays for each of the 100 cases evaluated. The
concordance correlation coefficients between the
expression levels of 22C3 and SP263 were 0.97 (0.95–
0.98), 0.97 (0.96–0.98), 096 (0.94–0.97), and 0.89 (0.84–
0.92) for centers A, B, C, and D, respectively, as reported
in Table 2 (boldface entries). The table also indicates
intercenter agreements for all the coder pairs.
A line corresponding to the 50% cutoff for both
clones is indicated in Figure 3. Analytical results of all
cases scored 50% or higher in at least one center are
reported in Table 3. In panel A, cases with a mean 22C3
or SP263 PD-L1 expression of 50% or higher are re-
ported. Note that all cases in panel A were scoredTable 1. Interrater Agreement for PD-L1 Expression Data at Di
PD-L1 Expression Cutoff 22C3 Test (95% CI)a
50% 0.95 (0.83–106)
1% 0.77 (0.65–088)
aFleiss’s k interrater agreement.
bLight’s k for all coder pairs.
PD-L1, programmed death ligand 1; CI, confidence interval.positive in at least two of the trained centers. Panel B
shows an additional two cases with a mean of PD-L1
expression less than 50%. At the cutoff of 50% or
higher, 15 cases (15%) were found to be positive with
both clones by center A. Fourteen of these 15 cases
(93%) were judged positive by center B and C. However,
the discordant case in the last two centers was not the
same and had an expression value slightly different from
that reported from the other centers (see Table 3,
boldface entries). The discordant case for center B (case
3A) was scored 45% with both clones. Similarly, the
discordant case for center C (case 2E) was scored 40%
with clone 22C3 and 55% with clone SP263. The
concordance of data obtained by the pathologist of
center D, who was not trained for PD-L1 assessment infferent Cutoff Levels
SP263 Test (95% CI)a 22C3 Test vs. SP263 Testb
0.97 (0.86–1.09) 0.99 (0.96–1)
0.82 (0.71–0.94) 0.80 (0.68–0.91)
Figure 3. Scatter diagrams illustrating the correlation between the programmed death ligand 1 immunohistochemical 22C3
pharmDx test (22C3) and in vitro diagnostics Ventana programmed death ligand 1 (SP263) expression levels in each of the four
centers. See the text for details.
November 2017 PD-L1 IHC Assays to Select NSCLC Patients 1659international training workshops, was lower: two of the
15 cases in panel A were classified as negative with clone
22C3 (cases 2E and 3H, both scored 40%); in addition,
the two cases in panel B that were scored negative with
the SP263 clone by the other three centers and with a
mean PD-L1 expression level less than 50% were scored
positive (cases 6D and 1G, which were scored 50% andTable 2. Concordance between PD-L1 Expression Levels Obtai
Centers
Center
Center 1 SP263
(95% CI)a
Center 2 S
(95% CI)a
Center 1 22C3 0.97 (0.95–0.98) 0.96 (0.95–0
Center 2 22C3 0.96 (0.94–0.97) 0.97 (0.96–
Center 3 22C3 0.94 (0.92–0.96) 0.94 (0.91–0
Center 4 22C3 0.94 (0.92–0.95) 0.94 (0.92–0
Note: Boldface indicates intracenter concordance.
aConcordant correlation coefficient.
PD-L1, programmed death ligand; CI, confidence interval.55%, respectively). Overall, center D reported four
discordant cases.
At the cutoff of 50% or higher, the concordances
(weighted k values) between 22C3 and SP263 data in
each center were 1, 1, and 0.96 (95% CI: 0.88–1) for
centers A, B, and C, respectively, and 0.844 (95% CI:
0.695–0,992) for center D. The average concordancened with the 22C3 and SP263 Tests in the Four Pathology
P263 Center 3 SP263
(95% CI)a
Center 4 SP263
(95% CI)a
.97) 0.96 (0.94–0.97) 0.93 (0.90–0.95)
0.98) 0.95 (0.93–0.97) 0.92 (0.88–0.94)
.95) 0.96 (0.94–0.97) 0.90 (0.86–0.93)
.96) 0.95 (0.92–0.96) 0.89 (0.84–0.92)
Table 3. PD-L1 Expression Data Reported from the Four Centers in All Cases with a Score of at Least 50% in at Least One
Center
Panel Case Clone Center A Center B Center C Center D Mean
A 3A 22-C3 50 45 55 50 50
SP-263 55 45 55 55 52.5
7A 22-C3 90 90 80 70 82.5
SP-263 85 80 80 75 80
9A 22-C3 60 55 65 70 62.5
SP-263 80 85 70 90 81.25
4B 22-C3 70 70 60 60 65
SP-263 70 65 70 70 68.75
9B 22-C3 55 65 50 52 55.5
SP-263 70 60 70 80 70
2C 22-C3 70 70 70 70 70
SP-263 80 70 80 60 72.5
3C 22-C3 55 55 55 55 55
SP-263 75 60 70 70 68.75
4C 22-C3 55 55 55 50 53.75
SP-263 55 60 55 50 55
12C 22-C3 60 70 60 50 60
SP-263 80 80 60 70 72.5
7D 22-C3 70 70 50 60 62.5
SP-263 75 70 70 70 71.25
2E 22-C3 65 55 40 40 50
SP-263 80 70 55 70 68.75
7E 22-C3 75 85 60 80 75
SP-263 70 80 60 60 67.5
12E 22-C3 65 55 55 70 61.25
SP-263 60 60 55 60 58.75
3F 22-C3 80 80 60 80 75
SP-263 80 80 70 52 70.5
3H 22-C3 60 60 55 40 53.75
SP-263 65 55 50 70 60
B 6D 22-C3 25 25 15 20 21.25
SP-263 35 35 30 55 38.75
1G 22-C3 35 25 20 20 25
SP-263 40 30 20 50 35
Note: Details in the test. Boldface indicate discordant values.
1660 Marchetti et al Journal of Thoracic Oncology Vol. 12 No. 11(Light’s k values) for the three trained centers at the
cutoff of 50% or higher was 0.99 (95% CI: 0.96–1) (see
Table 1). At the cutoff of 1% or higher, the concordances
between 22C3 and SP263 data were 0.83 (95% CI: 0.75–
0.88), 0.8 (95% CI: 0.68–0.92), 0.77 (95% CI: 0.64–0.89),
and 0.62 (95% CI: 0.46–0.77) for centers A, B, C, and D,
respectively. The average agreement for the three
trained centers at the cutoff of 1% or higher was 0.80
(95% CI: 0.68–0.91) (see Table 1).
The mean frequencies of lung adenocarcinomas
found to be positive with the 22C3 and SP263 tests were
37.3% and 41.3%, respectively, at the cutoff of 1% or
higher and 14.3% and 14.7%, respectively, at the cutoff
of 50% or higher.
Discussion
Identification and accurate evaluation of biomarkers
are critical steps for targeted therapy of patients withNSCLC, including immunotherapy with anti–PD-1/PD-L1
drugs.29 A number of clinical trials have recently shown
that IHC expression of PD-L1 in tumor tissue correlates
with better response rate and clinical outcome after
anti–PD-1 treatment with pembrolizumab. In the pivotal
KEYNOTE 01/010/024 studies, which led to FDA and
EMA approval of pembrolizumab for first- and second-
line treatment of patients with NSCLC, the PD-L1 22C3
IHC assay on the Dako Autostainer platform has been
used for patient selection.30–32 Whereas in the FDA
approval the drug’s administration is linked to an FDA-
approved test, the EMA more generally recommends
the use of a validated test.30–32 Because the Dako system
is not present in all pathology laboratories, a technical
issue suddenly emerged for PD-L1 IHC–based selection
of patients to be treated with pembrolizumab. A number
of harmonization studies have been conducted to deliver
analytical data for the main commercially available
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promise that at least some of the PD-L1 IHC assays might
be complementary.21–24 However, some considerations
that emerged from these previous projects must be
taken into account in evaluation of the data: (1) the
number of cases examined is still too limited to draw
definitive conclusions; (2) most projects were developed
to compare sections stained in a central laboratory, so
the impact of the preanalytical phase performed in
different centers was not assessable; (3) the studies
were usually performed on sections of resected tumors,
where an accurate comparison of the percentage of
immune-reactive neoplastic cells may be more chal-
lenging than that attainable on accurately selected tumor
areas; (4) several studies have been conducted with
research use–only reagents; and (5) some of the projects
were conducted in collaboration with commercial
companies.
This independent, multicenter study was specifically
conceived to compare the IVD Ventana PD-L1 (SP263)
test on the Ventana BenchMark platform with the IVD
PD-L1 IHC 22C3 pharmDx test on the Dako Autostainer
platform on selected tumor areas from a large series of
lung adenocarcinomas.
Our results indicate a high analytical correlation—
higher than the typical 90% within-assay agreement for
IHC—between the expression data obtained by the
different observers with each of the two commercially
available PD-L1 assays.28 Indeed, the concordance cor-
relation coefficient among the four raters was 97% with
both IHC tests (98% with both tests when the untrained
center was excluded).
At the cutoff of 50% or higher, which is used for the
selection of patients for first-line treatment with pem-
brolizumab,32 the interrater agreement was far higher
than 90%, especially when only the three trained centers
were considered (95% and 97% for the 22C3 and SP263
tests, respectively).
A different scenario emerged when the same cases
were classified with a cutoff of 1% or higher. The
interrater agreement decreased to 75% and 80% for
the 22C3 and SP263 data, respectively. When only the
three trained centers were considered, the agreement
was slightly improved (77% and 82% for the 22C3
and SP263 data, respectively). These results clearly
indicate that the overall agreement at a cutoff of 1% or
higher is lower, near 80%, and can potentially be
increased by a specific training. The lower interob-
server agreement at the cutoff of 1% that emerged in
this study is in keeping with data reported in a recent
PD-L1 expression harmonization project that included
the 22C3 and SP263 clones.23 Regardless of the results
of currently available clinical studies, these observa-
tions should prompt further consideration of theopportunity to adopting such a low cutoff (1%) for
clinical selection of patients to be treated with anti–
PD-L1 drugs. However, in the harmonization study by
Scheel et al., the interobserver agreement was similar
at all cutoffs.22
The present study showed a high analytical corre-
lation (more than 90% at the lower 95% CI value) (see
Table 2) between PD-L1 expression levels evaluated by
the 22C3 and SP263 tests in the three trained centers.
Similarly, at the cutoff of 50% or higher, a high degree
of concordance between 22C3 and SP263 data (96%–
100%) was observed for the three trained centers. The
concordance for center D was only 84%, which is
slightly lower than that requested (90%) by the Col-
lege of American Pathologists guidelines for IHC as-
says.28 The lower performance of center D was due to
the fact that at the cutoff of 50% or higher, discordant
results occurred in four cases (see Table 3). Because
these analytical data could reflect differences in the
preanalytical phase, high-resolution scanned images of
all discrepant cases stained with both antibodies in
center A were sent to center D. The four cases gave
discordant data in center D also when evaluated on
digitalized images, clearly indicating that it was a
matter of staining interpretation.
At the cutoff of 1% or higher, the concordance be-
tween 22C3 and SP263 data in the trained centers was
about 80% (77%, 80%, and 83%), whereas in the un-
trained center the concordance was much lower (62%).
These data clearly show the importance of a specific
training for pathologists to ensure reproducibility of
results across laboratories, especially at a low cutoff
level. The lower agreement between the data obtained
with the 22C3 and SP263 clones at the cutoff of 1% or
higher is mainly attributable to the lower (about 80%)
interrater agreement obtained at this cutoff level with
each clone, as previously discussed.
An additional finding that emerged from the current
study is the prevalence of PD-L1 expression at different
cutoffs in a series of 100 consecutive resected lung
adenocarcinoma collected from three Italian centers.
About 40% of the tumors were PD-L1–positive with both
clones at the cutoff of 1% or higher, whereas only about
15% of cases were positive at the cutoff of 50% or
higher. These results are in keeping with recently pub-
lished data on resected lung adenocarcinomas.33
In conclusion, our results demonstrate a high cor-
relation between PD-L1 IHC expression data obtained
with the 22C3 and SP263 tests in NSCLC. The agree-
ment is excellent at a cutoff of 50% or higher and still
within the range of the intraclone agreement for both
antibodies at a cutoff of 1% or higher. Although clinical
validation for this alternative staining approach is
lacking, our data suggest that the PD-L1 IHC 22C3
1662 Marchetti et al Journal of Thoracic Oncology Vol. 12 No. 11pharmDx and the VENTANA PD-L1 (SP263) assays
could be used interchangeably as an aid to select pa-
tients for first-line and second-line treatment with
specific targeted agents.Acknowledgments
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